Phase 3 RCT in 314 patients with stage IIB–IVA cervical cancer: tri-weekly vs weekly cisplatin chemoradiotherapy did not significantly improve 3-year recurrence-free survival (84.1% vs 78.7%; HR 0.71, P=0.28), but had fewer grade 3–4 haematological toxicities and better QOL.
RCTn = 314 patients
Ryu et al. A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study